乐
乐观
乐观 · 25%PYPD
$4.99
情景价格
$5.670
-0.146 (-2.58%)收盘时
Loading chart…
- 最高
- 5.930
- 开盘
- 5.820
- 成交量加权均价
- 5.65
- 成交量
- 242.04K
- 市值
- 20.15M
- 最低
- 5.360
- 成交额
- 1.37M
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
AI 分析 of PolyPid Ltd (PYPD)
买入PolyPid Ltd is a good buy right now, with a current price of $5.42 and a strong analyst price target of $10 from Oppenheimer, indicating a potential upside of 84%. The company has received FDA priority review for its product D-PLEX100, which could significantly enhance its market position and revenue streams. Additionally, the stock has shown a year-to-date change of +24.60%, reflecting positive momentum. However, the main risk is the ongoing net losses, with a reported loss of $7.8 million in Q2 2026, which investors should monitor closely.
估值指标
PolyPid Ltd（PYPD）当前预期市盈率为 0.00，5 年平均预期市盈率为 -1.47。
Alphio AI 对 PYPD 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
6.010-27CNBCMajor Wall Street Rating Updates
8.510-15NewsfilterPolyPid Unveils 'PolyPid 2030' Long-Term Strategy
9.508-19NASDAQ.COMPolyPid Reports Q2 Loss Reduction Amid Strategic Partnerships
9.007-29seekingalphaPolyPid Receives FDA Priority Review for D-PLEX100
9.007-29NASDAQ.COMPolyPid's D-PLEX100 Receives FDA Priority Review
PYPD 常见问题 —— 由 Alphio AI 解答
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
PolyPid Ltd is a good buy right now, with a current price of $5.42 and a strong analyst price target of $10 from Oppenheimer, indicating a potential upside of 84%. The company has received FDA priority review for its product D-PLEX100, which could significantly enhance its market position and revenue streams. Additionally, the stock has shown a year-to-date change of +24.60%, reflecting positive momentum. However, the main risk is the ongoing net losses, with a reported loss of $7.8 million in Q2 2026, which investors should monitor closely.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。